RNA Formulation Articles

  1. Capstan Therapeutics' Next Steps For In Vivo CAR Therapies 9/19/2022

    Capstan Therapeutics is a brand-new biotech company dedicated to developing and delivering precise in vivo cell engineering to patients. With $165 million in financing, Capstan Therapeutics aims to build on the foundational insights of leaders in mRNA and cell therapy from the University of Pennsylvania. Laura Shawver, Ph.D., leads the company as President and CEO, and on the heels of the biotech’s recent news, I caught up with her to learn more about the company’s plans for developing in vivo CAR therapies.

  2. mRNA Delivery Is More Than Just The Vehicle: Think Outside — & Inside — The LNP 9/14/2022

    This article is part three of a four-part series unpacking my biggest takeaways from the mRNA Therapeutics Summit, which took place in Boston on July 27 & 28, 2022.

  3. To Advance An mRNA “Platform,” Forget Traditional Operational Structures 9/11/2022

    This article is **part** **two** of a four-part series unpacking several best practices I gleaned from the mRNA Therapeutics Summit, which took place in Boston on July 27 & 28, 2022.

  4. The Current Landscape Of mRNA Vaccines In Clinical Research 3/17/2022

    With the Pfizer-BioNTech and Moderna products, mRNA vaccines made global headlines in 2021 in the fight against COVID-19. As we recognize National Immunization Awareness Month, this article shares how mRNA vaccines currently in clinical research and clinical trials may be soon used to fight HIV-1, herpes, cancer, and more.